Gain Therapeutics has set its sights on proving the effectiveness of its Parkinson’s disease therapy next year after the brain-penetrant small molecule demonstrated “peripheral target engagement” in a phase 1 trial.
Johnson & Johnson has taken another step toward realizing a return on its $6.5 billion nipocalimab bet, filing for FDA approval to challenge argenx and UCB for the generalized myasthenia gravis (gMG) market.
The poor performance of General Motors’ Chinese joint ventures is forcing the company to write down assets and take a restructuring charge totaling more than $5 billion in the fourth quarter of this year
U.S. officials are urging telecommunication companies to boost network security following a Chinese hacking operation that gave officials in Beijing access to the private texts and phone conversations of Americans
A U.S. Senate subcommittee has held a hearing to question the growing use of airline fees to charge passengers for things like early boarding and better seats
U.S. stock indexes rose to more records after tech companies talked up how much artificial intelligence is boosting their results
Proteins are made of chains of amino acids, and a basic tenet of biology is that the sequence of amino acids determines how a protein folds into a 3D shape which, in turn, dictates the protein’s function. But another tenet of biology is that rules are meant to be broken.
The effort to develop psychedelic therapies took a hit earlier this month when the FDA rejected Lykos Therapeutics’ MDMA-assisted therapy, a blow that was quickly followed by the retraction of three Lykos research papers and the slashing of 75% of the biotech’s workforce.
Foreign-made drugs are often unavailable in Japan due to the country’s approval process, which requires clinical trial data from Japanese patients. To address this issue, known as “drug loss,” Japanese technology company Fujitsu is partnering with American start-up Paradigm Health to attract global clinical trials to the island nation.
Illumina has secured an FDA approval to bring its pan-cancer tissue profiling test to U.S. shores.
FDA elevates 3 recalls of Smiths Medical ventilators, tracheostomy tubes
FDA issues draft guidance to help industry conduct global cancer clinical trials
Biohaven bounces back with phase 3 ultra-rare disease win, heads to FDA in bid to overturn prior refusal
AstraZeneca, Daiichi’s Trodelvy rival fails to improve overall survival in breast cancer trial
Stroke devicemaker Route 92 Medical raises $50M to go global
Black Diamond, Ideaya entertain registrational trial ideas as cancer drugs show midstage promise
Sanofi scoops negotiation rights to Ventyx obesity, Parkinson’s candidate for $27M
Context builds up bank of bispecific antibodies with up to $133M biobucks deal for BioAtla asset
European stock markets end year with gains
US Stock Markets to Remain Closed in Honor of Jimmy Carter on National Day of Mourning
